Molecular Mechanisms of Clinical Resistance to Targeted Therapy Among Patients With Breast Cancer

Active, not recruitingOBSERVATIONAL
Enrollment

269

Participants

Timeline

Start Date

January 9, 2007

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2026

Conditions
Breast Cancer
Interventions
OTHER

Blood draw

A single 10ml tube of blood will also be obtained for a comparison of patient's normal DNA for genomic analyses either at the time of the procedure or at a followup appointment if feasible.

OTHER

immunoenzyme technique

PROCEDURE

biopsy

PROCEDURE

histopathologic examination

Trial Locations (7)

10065

Memorial Sloan Kettering Cancer Center, New York

11553

Memorial Sloan Kettering Nassau (Consent only), Uniondale

11725

Memorial Sloan Kettering Commack (Consent only), Commack

07920

Memorial Sloan Kettering Basking Ridge (Consent only), Basking Ridge

07748

Memorial Sloan Kettering Monmouth (Consent only), Middletown

07645

Memorial Sloan Kettering Bergen (Consent only), Montvale

Unknown

Memorial Sloan Kettering Westchester (Consent only), Harrison

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT00897702 - Molecular Mechanisms of Clinical Resistance to Targeted Therapy Among Patients With Breast Cancer | Biotech Hunter | Biotech Hunter